论文部分内容阅读
目的:对3种不同抗生素方案治疗支气管肺炎婴幼儿的成本与可行性进行前瞻性研究。方法:2013-04-2014-09我院收治96例支气管肺炎患儿,将其随机分为A组(头孢曲松钠治疗)、B组(头孢他啶治疗)及C组(头孢噻肟钠治疗),3组各32例,比较3组的疗效、不良反应、治疗成本及成本/效果(C/E)。结果:A、B、C3组的总有效率分别为87.5%、90.6%、84,4%,组间比较差异无统计学意义,A、B、C 3组的C/E依次为1.9、2.6、1.6,组间比较差异有统计学意义(P<0.05)。结论:头孢他啶治疗支气管肺炎婴幼儿患者的疗效显著,且经济成本较低,相较于头孢曲松钠与头孢噻肟钠具有更高的临床推广意义。
OBJECTIVE: To prospectively study the cost and feasibility of three different antibiotic regimens for the treatment of infants with bronchopneumonia. Methods: Totally 96 children with bronchial pneumonia were admitted to our hospital from April 2013 to April 2014. They were randomly divided into group A (ceftriaxone sodium treatment), group B (ceftazidime treatment) and group C (cefotaxime sodium treatment) , 32 in each group. The curative effect, adverse reaction, treatment cost and cost / effect (C / E) of the three groups were compared. Results: The total effective rates of groups A, B and C3 were 87.5%, 90.6% and 84.4% respectively, there was no significant difference between the two groups. The C / E of groups A, B and C were 1.9, 2.6 , 1.6, the difference between the groups was statistically significant (P <0.05). Conclusion: Ceftazidime is effective in treating infants and children with bronchopneumonia. It has a lower economic cost compared with ceftriaxone sodium and cefotaxime sodium, which has a higher clinical promotion significance.